Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHighmark Delaware infliximab Prior Auth & Coverage…
    Ask Trek AI about this page
    CurrentHighmark DelawarePolicy N/A

    Outpatient Medical Injectable Infliximab Authorization (including biosimilars) - Coverage Criteria

    Customize your policy alerts

    Sign up for all Highmark Delaware policy alerts

    Know when Highmark Delaware releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Form and requirements for prior authorization of outpatient medical benefit infliximab (including biosimilars) for Highmark Delaware members; intended for prescribing clinicians, infusion providers, and billing offices requesting authorization.

    Policy Summary
    PayerHighmark Delaware
    PolicyOutpatient Medical Injectable Infliximab Authorization (coverage criteria)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a completed Outpatient Medical Injectable Infliximab Authorization form with site of care, drug/dose, diagnosis, member/provider details, and attached clinical documentation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6document chunks/pages

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4
    preferred/non-preferred groups
    8indications listed

    Coverage Criteria

    Authorization and product preference

    Coverage consideration per form fields and product preference

    Form completion and documentation: Authorization requires a completed form with member and provider identifiers, place of administration, requested drug name/strength/dose, directions, quantity (# of doses/visits), ICD-10 diagnosis code, member weight, indication, whether infliximab is combined with methotrexate, and attached pertinent clinical information including prior therapies tried/failed and date of last infusion.

    Based on required form fields

    Preferred product trial requirement for non-preferred: A non-preferred product (Remicade J1745 or Renflexis Q5104) will be considered only after documented drug therapy failure after an adequate therapeutic trial, or intolerance, or contraindication to BOTH preferred products (Avsola Q5121 and Inflectra Q5103).

    Explicit step/preference rule

    Medicare exception: Medicare members currently established on a non-preferred therapy are not required to try a preferred option.

    Form states exception for Medicare

    Non-preferred infliximab products listed on the form are Remicade (J1745) and Renflexis (Q5104). These non-preferred agents will be considered only after documentation shows an adequate therapeutic trial resulting in drug therapy failure, or documented intolerance, or a documented contraindication to both preferred products. Note: the form explicitly allows a Medicare exception — Medicare members currently established on a non-preferred therapy are not required to try a preferred option.

    Coding

    NON-PREFERREDHCPCSNot Covered
    J1745Remicade
    Q5104Renflexis
    PREFERRED for ALL indicationsHCPCSCovered
    Q5121Avsola
    Q5103Inflectra

    Provider Actions & Submission Requirements

    Prior Authorization

    Authorization submission requirements — use the Outpatient Medical Injectable Infliximab Authorization Request Form

    Submit the completed Outpatient Medical Injectable Infliximab Authorization Request Form with member and provider identifiers, place of administration, requested drug name/strength/dose/quantity, ICD-10 diagnosis code, member weight, site of care and drug dispensing method, and the physician/NPI and office contact information.

    • Form must indicate Place of Administration Type (home infusion, office professional, ambulatory infusion suite professional, or outpatient hospital).
    • Form must indicate Drug Dispensing Information (specialty pharmacy or buy & bill) and include dispensing provider name and NPI when applicable.
    • Include requested drug name, strength/dose, directions, quantity (# of doses/visits), and ICD-10 diagnosis code.
    Step Therapy

    Preference and step requirement for non-preferred products

    Non-preferred infliximab products (Remicade J1745, Renflexis Q5104) will only be considered after documentation of drug therapy failure after an adequate therapeutic trial, or intolerance, or contraindication to BOTH preferred products (Avsola Q5121 and Inflectra Q5103).

    Background

    Infliximab and its biosimilars are intravenous tumor necrosis factor (TNF)-alpha inhibitors used across multiple inflammatory conditions. The authorization form groups available products into preferred and non-preferred options and requires clinical details to support therapy (diagnosis, prior therapies, and response). For non-preferred agents, the policy requires documentation of failure, intolerance, or contraindication to both preferred infliximab biosimilars before consideration, although established Medicare beneficiaries on a non-preferred product are exempt from that trial requirement.

    Definitions

    Concomitant methotrexate use — Infliximab + Methotrexate
    DefinitionInfliximab being used in combination with Methotrexate
    Form fieldThe authorization form explicitly asks: 'Is Infliximab being used in combination with Methotrexate? — YES / NO'
    If not combinedIf NO is selected, the form requests an explanation in the provided free-text field
    Relevance to prior therapy documentationConcomitant methotrexate use is captured on the form alongside prior therapies tried and failed and disease severity
    Use in clinical indicationsConcomitant use is recorded for infliximab across listed indications (e.g., RA, PsA, AS, CD, UC, JIA, non-infectious uveitis)

    Initial Therapy Criteria

    Initial therapy

    Initial therapy selection and documentation

    Initial therapy form requirements: Specify requested drug name, strength/dose, directions, quantity (# of doses/visits), ICD-10 diagnosis code, member weight, indication (select diagnosis), and whether infliximab is combined with methotrexate; list previous therapies tried and failed if applicable.

    Form fields

    Continuation of Therapy Criteria

    Continuation of therapy

    Continuation requires documentation

    Continuation of therapy documentation: For continuation of therapy indicate date of last infusion and whether the member has demonstrated disease stability or a beneficial response to therapy; attach clinical records and mark continuation on the form.

    Form field

    Step Therapy Requirements

    StepRequirementPreferred products (must be tried)Non-preferred products (considered only after requirement met)
    1Documented drug therapy failure after an adequate therapeutic trial, OR intolerance, OR contraindication to BOTH preferred productsAvsola (Q5121); Inflectra (Q5103)Remicade (J1745); Renflexis (Q5104)

    Site of Care

    Note

    Specify site of care and facility billing status on the form

    Specify the site of care on the authorization form — select Home Infusion, Office - Professional, Ambulatory Infusion Suite - Professional, or Outpatient Hospital and indicate whether the site is hospital-affiliated or facility-billed.

    • Also indicate the drug dispensing method (Specialty Pharmacy or Buy & Bill) on the form.

    Biosimilar / Reference Product Information

    Billing Rule

    Preferred infliximab: Avsola (Q5121)

    Avsola (Q5121) is a preferred infliximab product for all indications and should be selected as the preferred agent when appropriate.

    • Preferred product selection is documented on the form under 'PREFERRED for ALL indications'.
    Billing Rule

    Preferred infliximab: Inflectra (Q5103)

    Inflectra (Q5103) is a preferred infliximab product for all indications and should be selected as the preferred agent when appropriate.

    • Preferred product selection is documented on the form under 'PREFERRED for ALL indications'.
    Policy Summary
    PayerHighmark Delaware
    PolicyOutpatient Medical Injectable Infliximab Authorization (coverage criteria)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a completed Outpatient Medical Injectable Infliximab Authorization form with site of care, drug/dose, diagnosis, member/provider details, and attached clinical documentation.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions & Submission RequirementsBackgroundDefinitionsInitial Therapy CriteriaContinuation of Therapy CriteriaStep Therapy RequirementsSite of CareBiosimilar / Reference Product Information
    • Medicare members already established on a non-preferred therapy are exempt from the preferred trial requirement.
    Documentation Required

    Required documentation to attach with authorization

    Attach all pertinent clinical information to the form, including whether this is a new start or continuation, date of last infusion, and whether the member has demonstrated disease stability or a beneficial response to therapy.

    • List all previous therapies tried and failed.
    • Indicate diagnosis (selected from form), member weight, and whether infliximab is being used in combination with methotrexate.
    • Mark Attached: YES/NO and specify New Start or Continuation of Therapy.
    Denial Risk

    Triggers for possible denial

    Requests may be denied if required fields or supporting clinical information are missing or if prior therapy trials or failures to preferred products (when required) are not documented.

    • Missing member/provider/place of administration details, dose, dates, or ICD-10 diagnosis may trigger denial.
    • Failure to document prior therapies tried and failed, or failure/intolerance to both preferred agents when requesting a non-preferred product, may trigger denial.
    • Not attaching pertinent clinical information or indicating date of last infusion and response to therapy may result in denial.